

Trinity Health Grand Haven Hospital
 Cumulative Antimicrobial Susceptibility Summary Jan. 1, 2024 - Dec. 31, 2024
 BioMerieux Vitek® 2 MIC Methodology

NON-URINE SOURCE

Organism	%Susceptible																										
	# Isolates	Ampicillin	Amp/Sulbactam	Cefazolin	Cefepime	Ceftazidime	Ceftriaxone	Ciprofloxacin	Clindamycin	Daptomycin	Doxycycline	Ertapenem	Erythromycin	Gentamicin	Gentamicin (high level)	Levofloxacin	Linezolid	Meropenem	Moxifloxacin	Oxacillin	Pi p/Tazobactam	Rifampicin	Streptomycin (high level)	Tetracycline	Tigecycline	T/S	Vancomycin
<i>Coagulase Negative Staph</i>	21 ¹	*	*	*	*	*	*	90	48	100	90	*	43	95	*	90	100	*	100	52	*	100	*	90	100	76	100
<i>Enterococcus faecalis</i>	52	100	*	*	*	*	*	81	*	100	27	*	17	*	94	83	100	*	*	*	*	*	96	25	100	*	94
<i>Escherichia coli</i>	65	68	74	71	88	86	86	82	*	*	*	100	*	92	*	82	*	100	*	*	97	*	*	*	*	78	*
<i>Pseudomonas aeruginosa</i>	48	*	*	*	90	92	*	85	*	*	*	*	*	96	*	83	*	98	*	*	90	*	*	*	*	*	*
<i>Staphylococcus aureus</i>	133	*	*	*	*	*	*	77	77	100	95	*	55	100	*	77	100	*	93	76	*	100	*	92	100	97	100
<i>Methicillin Resistant Staph aureus</i>	31	*	*	*	*	*	*	32	77	100	90	*	13	100	*	32	100	*	81	0	*	100	*	87	100	97	100
<i>Methicillin Susceptible Staph aureus</i>	102	*	*	*	*	*	*	90	76	100	97	*	68	100	*	91	100	*	97	100	*	100	*	93	100	97	100

URINE SOURCE

Organism	%Susceptible																									
	# Isolates	Ampicillin	Amp/Sulbactam	Cefazolin	Cefepime	Ceftazidime	Ceftriaxone	Ciprofloxacin	Daptomycin	Doxycycline	Ertapenem	Gentamicin	Gentamicin (high level)	Levofloxacin	Linezolid	Meropenem	Moxifloxacin	Nitrofurantoin	Oxacillin	Pi p/Tazobactam	Rifampicin	Streptomycin (high level)	Tetracycline	Tigecycline	T/S	Vancomycin
<i>Coagulase negative staph</i>	54	*	*	*	*	*	*	89	100	98	*	94	*	89	100	*	94	100	55	*	98	*	85	100	80	100
<i>Enterococcus faecalis</i>	112	100	*	*	*	*	*	89	100	24	*	*	88	89	93	*	*	99	*	*	*	97	21	100	*	97
<i>Escherichia coli</i>	793	63	72	95	95	94	94	90	*	*	100	94	*	90	*	100	*	96	*	97	*	*	*	*	84	*
<i>ESBL-producing E Coli</i>	38	0	29	0	16	16	5	21	*	*	97	79	*	21	*	100	*	84	*	81	*	*	*	*	58	*
<i>Klebsiella oxytoca</i>	24 ¹	0	75	*	96	92	92	96	*	*	100	92	*	100	*	100	*	88	*	96	*	*	*	*	92	*
<i>Klebsiella pneumoniae</i>	139	0	84	*	93	89	89	91	*	*	99	94	*	92	*	100	*	23	*	94	*	*	*	*	85	*
<i>Proteus mirabilis</i>	90	91	98	100	100	100	100	62	*	*	100	94	*	62	*	100	*	0	*	100	*	*	*	*	78	*
<i>Pseudomonas aeruginosa</i>	60	*	*	*	98	98	*	93	*	*	*	100	*	93	*	97	*	*	*	100	*	*	*	*	*	*
<i>Staphylococcus aureus</i>	24 ¹	*	*	*	*	*	*	42	100	92	*	88	*	42	100	*	75	100	42	*	100	*	83	100	88	100
<i>Methicillin Resistant Staph aureus</i>	14 ¹	*	*	*	*	*	*	14	100	86	*	79	*	14	100	*	64	100	0	*	100	*	79	100	86	100
<i>Methicillin Susceptible Staph aureus</i>	10 ¹	*	*	*	*	*	*	80	100	100	*	100	*	80	100	*	90	100	100	*	100	*	90	100	90	100

*Drug not tested or drug not indicated

¹less than desirable # of isolates for statistical validity, ≥30 isolates is considered clinically significant

Trinity Health Grand Haven Hospital
 Cumulative Antimicrobial Susceptibility Summary Jan. 1, 2024 - Dec. 31, 2024
 BioMerieux Vitek® 2 MIC Methodology

NON-URINE SOURCE

Organism	%Susceptible															
	# Isolates	Ari kaci n	Ampx/ Cl av Aci d	Azt reonam	Cefot axi me	Cefpodoxi ne	Ceft az/ Avi bact an	Ceft / Tazobact am	Doxycycli ne	Eravacycli ne	I m i penem	Mer o/ Vabor bact an	M nocycli ne	Pol ym xi n B	Tigecycline	Tobramyci n
<i>Escherichia coli</i>	41	100	88	83	80	78	100	100	76	100	98	100	95	*	100	91
<i>Pseudomonas aeruginosa</i>	12 ¹	100	*	*	*	*	100	100	*	*	93	*	*	100	*	100

URINE SOURCE

Organism	%Susceptible															
	# Isolates	Ari kaci n	Ampx/ Cl av Aci d	Azt reonam	Cefot axi me	Cefpodoxi ne	Ceft az/ Avi bact an	Ceft / Tazobact am	Doxycycli ne	Eravacycli ne	I m i penem	Mer o/ Vabor bact an	M nocycli ne	Pol ym xi n B	Tigecycline	Tobramyci n
<i>Escherichia coli</i>	79	100	84	87	84	82	100	96	78	100	100	100	92	*	100	91
<i>ESBL-producing E Coli</i>	10 ¹	100	30	30	0	0	100	78	40	100	100	100	100	*	100	43
<i>Klebsiella pneumoniae</i>	17 ¹	100	100	88	82	82	100	94	71	100	100	100	76	*	100	94
<i>Pseudomonas aeruginosa</i>	13 ¹	100	*	*	*	*	100	100	*	*	87	*	*	92	*	100

*Drug not tested or drug not indicated

¹less than desirable # of isolates for statistical validity, ≥30 isolates is considered clinically significant